A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Recruiting · NCT06914037 · Registry updated 2025-04-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Phase 1 | 2025-04-06 | NCT06914037 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd. | 4 |
| Tianjin Medical University Cancer Institute and Hospital | 287 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Tianjin Medical University Cancer Institute & Hospital | Tianjin | China | 23 |